Subsequent analyses answered fundamental questions such as prevalence rates in different tumor types, whether the fusions were enriched in any of these tumors, percentage of MET as the 3' partner and carriers of multiple fusions, location of the MET sequence, and breakpoints and partners. Here, MET is linked to neoplasm.